FA
TXMD icon

Fedenia Advisers’s TherapeuticsMD TXMD Stock Holding History

Fedenia Advisers’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88 Buy
+40
New +$83 ﹤0.01% 459
2025
Q1 		– Sell
-40
Closed -$34 – 408
2024
Q4 		$34 Buy
+40
New +$56 ﹤0.01% 456

Other funds holding TXMD

SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
PWA
Provenance Wealth Advisors Fort Lauderdale, Florida $1.05B AUM 18.67% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return
SWIM
Smallwood Wealth Investment Management Red Bank, New Jersey $229M AUM 23.56% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Fedenia Advisers's TXMD Position: Q2 2026 in Review

Fedenia Advisers opened a new position in TherapeuticsMD (TXMD) in Q2 2026: 40 shares worth $88. The stake represents ﹤0.01% of the portfolio and ranks #459 among its holdings. This is a return to the name: Fedenia Advisers previously reported a position in TXMD as recently as Q4 2024.

Fedenia Advisers first reported a position in TXMD in Q4 2024 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Fedenia Advisers held 40 shares of TherapeuticsMD worth $88 as of Q2 2026.
  • TherapeuticsMD was a new Fedenia Advisers position in Q2 2026.
  • TherapeuticsMD made up ﹤0.01% of Fedenia Advisers's portfolio in Q2 2026, its #459 holding.
  • Fedenia Advisers first reported a position in TherapeuticsMD in Q4 2024 and has held it in 2 quarters since.
  • 9 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Fedenia Advisers's 13F filing for Q2 2026, filed 22 Jul 2026.